Cerylid Biosciences Ltd.
This article was originally published in Start Up
Executive Summary
Cerylid Biosciences Ltd. is tapping the pharmaceutical potential in a collection of some 600,000 extracts of plants, microbes, and marine macroorganisms from Australia and South East Asia. The firm says it has identified nearly 350 active molecules, and has taken three into development. The company is keen to expose its libraries to good targets, and so is seeking partners.
You may also be interested in...
Natural Products: Providing Diversity or Drug Candidates?
There is tremendous value to be had in exploiting the pharmaceutical uses of natural products, but few companies built around natural-product platforms have enjoyed much success. To succeed, these companies shouldn't be focused on merely providing chemical diversity to the drug industry. Instead, they need to articulate how their libraries will allow them to close in, quickly and with a relatively low risk of failure, on specific drugs for specific diseases.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.